Company Overview - Phio Pharmaceuticals Corp is a clinical-stage biotechnology company developing therapeutics using its INTASYL® siRNA gene silencing technology to enhance the immune system's ability to kill cancer cells [9] - The company's lead clinical program, PH-762, is an INTASYL compound targeting PD-1 and is being evaluated in a Phase 1b trial for treating skin cancers including cutaneous SCC, melanoma, and Merkel cell carcinoma [10] Financing Activity - The company announced a $1.15 million registered direct offering of 437,192 shares of common stock at $2.635 per share [2][3] - Concurrently, the company will issue unregistered warrants to purchase up to 437,192 shares of common stock at $2.51 per share, exercisable immediately and expiring in five years [3] - H C Wainwright & Co is acting as the exclusive placement agent for the offering [4] - The net proceeds will be used for working capital and general corporate purposes [4] Regulatory Information - The common stock offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC on May 20, 2024 and effective July 1, 2024 [5] - The warrants and underlying shares are being issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and are not registered under the Securities Act or state securities laws [6]

Berkshire Hathaway Chairman Warren Buffett is a value investor at his core. Value investing involves finding stocks trading below their intrinsic value and buying them at a discount. While the concept often sounds like a no-brainer, value investing is much more difficult than it sounds because many stocks are on sale for a reason. Investors will grapple over whether a stock is truly of value or whether it's a value trap.One equity holding in Berkshire's portfolio has found itself in the middle of this very ...

This stock-split stock can surge in line with broader market optimism.The U.S. stock market has been on a winning streak in 2024, with the technology-heavy Nasdaq Composite index topping the 20,000 mark. A major part of this rally can be attributed to the rapid adoption of artificial intelligence (AI) across industries and functions.The AI wave is far from over. Enterprises worldwide are increasingly shifting their focus from AI-optimized infrastructure to complex AI applications.Historically, major technol ...

The ProShares UltraPro QQQ TQQQ, which provides triple-leveraged exposure to the Nasdaq-100 Index, fell some 10.81% to $82.09 Wednesday after the Federal Reserve's December meeting.What To Know: The ETF is sensitive to bullish sentiment in tech stocks, which struggled amid concerns over the Fed's cautious outlook on monetary easing.While the Fed reduced the federal funds rate by 25 basis points to a range of 4.25%-4.5%, projections for only two additional rate cuts in 2025 dampened investor enthusiasm.Read ...

The year 2024 represented the best and worst of times for Super Micro Computer (SMCI 1.08%). The server maker started the year with a bang, reporting triple-digit revenue growth, thanks to demand from artificial intelligence (AI) customers. In fact, Supermicro's quarterly revenue this year surpassed annual revenue as recently as 2021. The company also went on to reach other important milestones, such as winning invitations to join the S&P 500 and the Nasdaq 100.All of this helped Supermicro soar 1,200% in j ...

The holidays have come early for a couple of this year's most-watched technology companies. I'm talking about Palantir Technologies (PLTR -1.80%) and MicroStrategy (MSTR -5.41%), software players that have soared more than 300% and 500%, respectively, this year. The Nasdaq-100, an index of the top 100 nonfinancial stocks trading on the Nasdaq Stock Market, invited the two companies to join as of Dec. 23.That's fantastic news for Palantir and MicroStrategy and their investors for a couple of reasons. First, ...

The Nasdaq Composite (^IXIC -0.32%) has advanced 34% year to date, and history says that momentum may carry into 2025. Since its inception in 1971, the Nasdaq has returned at least 20% in 20 years, and at least 30% in 12 years. After those performances, the index typically generated strong returns in the next 12 months, as detailed below:After a 20%-plus gain in a calendar year: The Nasdaq has returned an average of 17% during the next year.After a 30%-plus gain in a calendar year: The Nasdaq has returned a ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Leading U.S. exchange by number of IPOs and proceeds raised for the sixth consecutive year Featured the largest IPO and switch Over 500 exchange transfers to Nasdaq since 2005 NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on Nasdaq in 2024, representing an 81% win rate of Nasdaq-eligible IPOs in the U.S. market, and extendi ...

Leading U.S. exchange by number of IPOs and proceeds raised for the sixth consecutive year Featured the largest IPO and switch Over 500 exchange transfers to Nasdaq since 2005 NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on Nasdaq in 2024, representing an 81% win rate of Nasdaq-eligible IPOs in the U.S. market, and extend ...